MedTrace Logo

Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO

NCT03223428 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 223

Last updated 2024-07-24

Study results available
· View outcomes & findings →

Summary

The primary objective of the study is to estimate the proportion of carcinoid syndrome (CS) patients who are satisfied with their overall symptom control, 6 months after initiating treatment with telotristat ethyl (XERMELO).

Conditions

  • Carcinoid Syndrome

Interventions

DRUG

Xermelo

This study will include patients with carcinoid syndrome who are initiating treatment with XERMELO.

Sponsors & Collaborators

  • TerSera Therapeutics LLC

    lead INDUSTRY

Principal Investigators

  • Janine North, BS · TerSera Therapeutics LLC

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-22
Primary Completion
2022-01-14
Completion
2022-01-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03223428 on ClinicalTrials.gov